<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809702</url>
  </required_header>
  <id_info>
    <org_study_id>BPKoirala</org_study_id>
    <nct_id>NCT03809702</nct_id>
  </id_info>
  <brief_title>Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia</brief_title>
  <official_title>Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia and for the Prevention of Post Herpetic Neuralgia- a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B.P. Koirala Institute of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Grants Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B.P. Koirala Institute of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All eligible Herpes Zoster patients will be randomized into two groups. Group 1 will be the&#xD;
      treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other&#xD;
      routine treatment. Whereas, group 2 will be the control group receiving all routine treatment&#xD;
      similar to group 1 except Pregabalin. Instead control group will receive Placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study wants to see the role of Pregabalin in acute herpetic neuralgia pain reduction and&#xD;
      for the prevention of post herpetic neuralgia incidence as compared to placebo group. For&#xD;
      this purpose, all eligible Herpes Zoster patients will be randomized into two groups (41&#xD;
      patients in each group i.e.82 total patients). Group 1 will be the treatment group receiving&#xD;
      Pregabalin 75 mg twice daily for 4 weeks in addition to other routine treatment. Whereas,&#xD;
      group 2 will be the control group receiving all routine treatment similar to group 1 except&#xD;
      Pregabalin. Instead of pregabalin, control group will receive Placebo. The pain will be&#xD;
      evaluated in all patients in each follow visits (weekly follow up for 4 weeks then monthly&#xD;
      follow up for next three months). If it is difficult for the patient to present physically,&#xD;
      telephonic follow up will be done to find the pain score in the required time. Also, DLQI&#xD;
      (Dermatological life quality index) will be assessed at the first and last visit of the&#xD;
      patient.&#xD;
&#xD;
      At the end, pain score will be compared between the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction of visual analogue scale (VAS) of pain in each visit in intervention and placebo group</measure>
    <time_frame>Eight months</time_frame>
    <description>Percentage reduction of visual analogue scale (VAS) of pain in each follow up visits in intervention group as compared to the placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of Post Herpetic Neuralgia</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of post herpetic neuralgia in pregabalin group and placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Pregabalin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)</description>
    <arm_group_label>Pregabalin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of HZ presenting within 72 hours of onset of rash,&#xD;
&#xD;
          -  With pain score 40 or above on 100 mm pain Visual Analogue Scale at the screening&#xD;
             visit,&#xD;
&#xD;
          -  Giving written consent for the study.&#xD;
&#xD;
          -  Age between 18-70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HZ presenting after 72 hours of onset&#xD;
&#xD;
          -  Pain score less than 40 at baseline&#xD;
&#xD;
          -  Who took the stable doses of oral analgesics like: NSAIDs, acetaminophen, opioids and&#xD;
             antidepressant within six hours of screening visit&#xD;
&#xD;
          -  Using Pregabalin and Gabapentin within last 72 hours&#xD;
&#xD;
          -  Nerve block therapy within the last 48 hours&#xD;
&#xD;
          -  History of hypersensitivity to the drug or its ingredients&#xD;
&#xD;
          -  Use of topical medications within 12 hours&#xD;
&#xD;
          -  Unable to come for follow up because of severe systemic illness&#xD;
&#xD;
          -  Significant hepatic and renal disease,&#xD;
&#xD;
          -  Bed ridden patients or those who are physically unfit for follow up visits.&#xD;
&#xD;
          -  Ethically considered vulnerable members- pregnant/lactating mothers/newborn/children&#xD;
             below 12 years /physically or mentally challenged individuals/HIV/ AIDS/IV drug users&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchana Marahatta, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>B.P. Koirala Institute of Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>B P Koirala Institute of Health Sciences</name>
      <address>
        <city>Dharān Bāzār</city>
        <state>Province 1</state>
        <zip>7053</zip>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>B.P. Koirala Institute of Health Sciences</investigator_affiliation>
    <investigator_full_name>Dr Suchana Marahatta</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Herpes Zoster</keyword>
  <keyword>Herpetic neuralgia</keyword>
  <keyword>Pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

